Standard BioTools (LAB) has posted a mixed set of FY 2025 numbers, with Q4 revenue at US$23.8 million and basic EPS of US$0.04, even as trailing twelve month figures still show a loss with EPS at US$0.15 and net income from continuing operations at a loss of US$58.8 million. The company has seen quarterly revenue range from US$19.6 million to US$23.8 million across 2025, while basic EPS has moved between a loss of US$0.08 in Q3 and a small profit of US$0.04 in Q4. This sets up a story where investors are weighing a recent quarterly EPS improvement against the broader unprofitable trend. Overall, margins remain pressured on a trailing basis, so the key question is whether the latest quarter marks the start of a more sustainable earnings profile or just a temporary lift.

See our full analysis for Standard BioTools.

With the headline numbers on the table, the next step is to see how this earnings profile lines up against the widely followed narratives around growth, profitability, and execution for LAB, and where those stories might need updating.

Q4 swing to US$13.9 million profit stands out against full year loss

• Net income from continuing operations moved from a loss of US$31.7 million in Q3 2025 to a profit of US$13.9 million in Q4 2025. The trailing twelve months still show a loss of US$58.8 million, so the quarterly profit sits against a much larger recent loss history.
• Bulls point to cost synergies and operational streamlining as profit drivers, and this quarterly profit aligns with that view. However, it sits beside trailing twelve month losses of US$58.8 million and a five year pattern where losses have grown about 10.5% per year. Investors have to decide whether they see Q4 as an early sign of the bullish margin narrative or just a single good quarter.
  • Supporters of the bullish view highlight merger related cost savings that are expected to improve margins. This is consistent with Q4 profitability after three earlier quarterly losses in 2025 of US$23.4 million, US$17.7 million and US$31.7 million.
  • At the same time, the risk summary flags that the company is unprofitable over the last twelve months and is forecast to remain unprofitable over the next three years. The bullish claim of sustained margin improvement is therefore not yet supported by the longer term figures.

Bulls argue this kind of sharp quarterly turnaround could be the early sign of a broader profitability story, and you can see how they frame that in the 🐂 Standard BioTools Bull Case

Premium 5.3x P/S against peers despite losses

• LAB is on a P/S of 5.3x compared with 2.8x for the broader US Life Sciences group and 2.4x for peers. This higher sales multiple sits alongside trailing twelve month net income from continuing operations of a US$58.8 million loss and trailing EPS of a US$0.15 loss.
• Bears argue that paying more than double the peer P/S for a business that is loss making and expected to see revenue decline around 0.4% per year leaves limited room for disappointment, especially when trailing twelve month revenue of US$85.3 million is paired with losses that have grown about 10.5% per year over five years.
  • Critics highlight that forecasts call for LAB to remain unprofitable over the next three years while revenue is expected to drift lower. This makes a 5.3x P/S look demanding against the 2.8x industry level given the lack of projected near term profits.
  • The same risk summary that flags this premium multiple also points to continued unprofitability as a key risk, so the bearish view that the current valuation asks a lot from a loss making business is grounded in the combination of elevated P/S and negative trailing earnings.

Skeptics focus on whether a premium P/S can hold up if losses continue, and that cautious case is laid out in the 🐻 Standard BioTools Bear Case

DCF fair value of US$4.37 versus US$1.17 share price

• The DCF fair value estimate of US$4.37 sits well above the current share price of US$1.17. This implies a large valuation gap at the same time as the company carries a trailing twelve month loss of US$58.8 million and a forecast of continued unprofitability over the next three years.
• Consensus style narratives often reference this type of valuation gap as potential upside. Yet the same data set shows losses increasing about 10.5% per year over five years and a modest forecast revenue decline of roughly 0.4% per year, so the tension for investors is between a model that suggests room above US$1.17 and operating trends that still point to weak profitability.
  • Supporters of the fair value argument can point to the stock trading materially below that US$4.37 DCF fair value estimate while also acknowledging that LAB is currently unprofitable and is expected to stay that way for at least three years.
  • Investors who are more cautious may focus on the combination of a premium 5.3x P/S and ongoing losses and decide that, even with a higher modelled value, the negative

  Next Steps

  To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Standard BioTools on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

  If this mix of premium valuation, ongoing losses and modelled upside feels like a tug of war, do not wait around for someone else to decide what it means. Take a closer look at the key drivers, then weigh up the balance of 1 key reward and 1 important warning sign to decide where you stand.

  Explore Alternatives

  LAB combines a premium 5.3x P/S multiple with ongoing losses, trailing EPS of a US$0.15 loss and forecasts that still point to unprofitability.

  If you are uneasy paying up for a company with pressured margins and no clear path to profits yet, take a look at 52 high quality undervalued stocks that pair more grounded valuations with stronger underlying fundamentals right now.

  This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.